Objective: Although aortofemoral bypass (AoFB) is the standard treatment for challenging aortoiliac occlusive disease (AIOD), less-invasive treatments, such as axillofemoral bypass (AxFB) or endovascular treatment (EVT) have been conducted for patients with severe comorbidities. In this study, we compared the clinical outcomes between AxFB and EVT for AIOD. Materials and Methods: We retrospectively reviewed 9 patients with AxFB and 10 with EVT for challenging AIOD. The patients' information and operative results were evaluated. The rates of patency and limb salvage were analyzed according to the Kaplan-Meier method. Results: In the EVT group, 5 of 10 (50%) patients had aortic stenting alone, 3 (30%) received aorto-uniiliac stenting, and 2 (20%) received aorto-biiliac stenting. In the AxFB group, 2 cases (22.2%) showed acute graft thrombosis; however, in the EVT group, no acute thrombotic complications were seen. The primary patency rates in the AxFB and EVT groups at 5 years were 53.6% and 81.2%, respectively (log rank P=0.225), and the assisted primary patency rates at 5 years were 53.6% and 100%, respectively (log rank P=0.012). Conclusion: EVT exhibited a more durable, better long-term patency rate than AxFB. EVT may, therefore, be a viable treatment alternative to AoFB for challenging AIOD.
Objective: Although aortofemoral bypass (AoFB) is the standard treatment for challenging aortoiliac occlusive disease (AIOD), less-invasive treatments, such as axillofemoral bypass (AxFB) or endovascular treatment (EVT) have been conducted for patients with severe comorbidities. In this study, we compared the clinical outcomes between AxFB and EVT for AIOD. Materials and Methods: We retrospectively reviewed 9 patients with AxFB and 10 with EVT for challenging AIOD. The patients' information and operative results were evaluated. The rates of patency and limb salvage were analyzed according to the Kaplan-Meier method. Results: In the EVT group, 5 of 10 (50%) patients had aortic stenting alone, 3 (30%) received aorto-uniiliac stenting, and 2 (20%) received aorto-biiliac stenting. In the AxFB group, 2 cases (22.2%) showed acute graft thrombosis; however, in the EVT group, no acute thrombotic complications were seen. The primary patency rates in the AxFB and EVT groups at 5 years were 53.6% and 81.2%, respectively (log rank P=0.225), and the assisted primary patency rates at 5 years were 53.6% and 100%, respectively (log rank P=0.012). Conclusion:EVT exhibited a more durable, better long-term patency rate than AxFB. EVT may, therefore, be a viable treatment alternative to AoFB for challenging AIOD.
Authors: T Onohara; K Komori; M Kume; M Ishida; S Ohta; K Takeuchi; T Matsumoto; K Sugimachi Journal: J Cardiovasc Surg (Torino) Date: 2000-12 Impact factor: 1.888
Authors: Victor Aboyans; Jean-Baptiste Ricco; Marie-Louise E L Bartelink; Martin Björck; Marianne Brodmann; Tina Cohnert; Jean-Philippe Collet; Martin Czerny; Marco De Carlo; Sebastian Debus; Christine Espinola-Klein; Thomas Kahan; Serge Kownator; Lucia Mazzolai; A Ross Naylor; Marco Roffi; Joachim Röther; Muriel Sprynger; Michal Tendera; Gunnar Tepe; Maarit Venermo; Charalambos Vlachopoulos; Ileana Desormais; Petr Widimsky; Philippe Kolh; Stefan Agewall; Héctor Bueno; Antonio Coca; Gert J De Borst; Victoria Delgado; Florian Dick; Cetin Erol; Marc Ferrini; Stavros Kakkos; Hugo A Katus; Juhani Knuuti; Jes Lindholt; Heinrich Mattle; Piotr Pieniazek; Massimo Francesco Piepoli; Dierk Scheinert; Horst Sievert; Iain Simpson; Jakub Sulzenko; Juan Tamargo; Lale Tokgozoglu; Adam Torbicki; Nikolaos Tsakountakis; José Tuñón; Melina Vega de Ceniga; Stephan Windecker; Jose Luis Zamorano Journal: Eur J Vasc Endovasc Surg Date: 2017-08-26 Impact factor: 7.069
Authors: Russell H Samson; Ricardo Morales; David P Showalter; Michael R Lepore; Deepak G Nair Journal: J Vasc Surg Date: 2016-04-29 Impact factor: 4.268
Authors: S el-Massry; E Saad; L R Sauvage; M Zammit; C C Davis; J C Smith; E A Rittenhouse; L D Fisher Journal: J Vasc Surg Date: 1993-01 Impact factor: 4.268
Authors: F A B Grimme; P C J M Goverde; P J E M Verbruggen; C J Zeebregts; M M P J Reijnen Journal: Eur J Vasc Endovasc Surg Date: 2015-09-03 Impact factor: 7.069